Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series

Table 1

Characteristics of all patients in this series and of the subset that was evaluable for response to vinorelbine treatment.

	All patients 𝑛=87 (%)	Evaluable for response patients 𝑛=70 (%)
Age, median [range]	63 [32–85]	61 [32–85]
OS median [range]	16 months [5–83]	11.5 months [1–83]
Follow-up (patients alive)
median [range]	13 months [3–50]	12 months [1–50]
Hormonal status
ER/PR positive	73 (83.9)	60 (85.7)
ER/PR negative	14 (16.1)	10 (14.3)
Treatment
Vinorelbine monotherapy	62 (71.3)	48 (68.6)
Vinorelbine + trastuzumab	25 (28.7)	22 (31.4)
Line of treatment
1st line	67 (77)	54 (77.1)
2nd or later	20 (23)	16 (22.9)